|
Mechanism5-HT2 receptor antagonists [+3] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date28 May 2021 |
/ Not yet recruitingPhase 3 A Randomized, Double-blind, Double-dummy, Positive Drug Parallel Controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
The goal of this [clinical trial] is to [evaluate the safety and efficacy of olanzapine-samidorphan tablets] in [adults with schizophrenia]. The main question[s] it aims to answer are:
* [question 1] Olanzapine-samidorphan significantly mitigate weight gain better than olanzapine.
* [question 2] Olanzapine- samidorphan and olanzapine have similar antipsychotic efficacy.
A Phase 1, Open-Label Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan in Healthy Lactating Women
This clinical lactation study is to provide information regarding the PK and amount of OLZ/SAM in breast milk and estimated infant exposure.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM Vs Olanzapine to Evaluate Weight Gain As Assessed by Change in BMI Z-Score in Pediatric Subjects with Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth)
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
100 Clinical Results associated with D1 receptor x D2 receptor x μ opioid receptor x 5-HT2 receptor
100 Translational Medicine associated with D1 receptor x D2 receptor x μ opioid receptor x 5-HT2 receptor
0 Patents (Medical) associated with D1 receptor x D2 receptor x μ opioid receptor x 5-HT2 receptor